Official ESCRS | European Society of Cataract & Refractive Surgeons


Combined phacoemulsification with iStent or XEN or endo-cyclodiode: two years' retrospective outcomes

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma II

Venue: Poster Village: Pod 3

First Author: : A.Roble UK

Co Author(s): :    H. Ali   T. Kersey                    

Abstract Details


To evaluate the safety and efficacy of combined phacoemulsification with iStent or Xen implant or Endocyclodiode (ECP).


Single centre teaching hospital.


A single centre restrospective study of patients with primary open angle (POA) or primary angle closure (PAC) or ocular hypertension (OHT) on at least one medication who underwent combined phacomeulsification with either Xen implant or iStent or endocylodiode. Post-operatively patients were assessed at months 3, 6, 12, 18 and 24. The intraocular pressure (IOP), number of glaucoma medications, visual acuity and presence of complications were assessed. Primary outcome was defined as IOP reduction of at least 20% with or without glaucoma medications.


A total of 425 eyes were included across three arms. At 2 years, mean post-operative IOP was reduced in all groups from baseline pre-operative IOP. For Xen this was from 18.8 to to 13.8mmHg, iStent from 17.8 to 13.2 and ECP from 18.1 to 15.3.  A 20% reduction from baseline IOP was 40.1%, 41.1% and 39.1% in Xen, iStent and ECP respectively. A 40% reduction from baseline was 19.8%, 14.2% and 16.3% in the Xen, iStent and ECP groups respectively. Reductions in glaucoma medications were seen in patients on one medication across the three arms at 2 years.


Combined phacoemulsification surgery with MIGs procedures was effective and safe in lowering the IOP and number of glaucoma medications at 2 years.

Financial Disclosure:


Back to previous